What are the side effects of Imdelltra (Tarlatamab-dlle)?

Imdelltra (Tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed during or after platinum-based chemotherapy. In its clinical studies, common side effects include cytokine release syndrome, fatigue, fever, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia and nausea. These adverse reactions occurred in more than 20% of patients.

In addition, there are some laboratory abnormalities. Grade 3 or 4 laboratory abnormalities that occurred in more than 2% of patients included lymphopenia, decreased sodium, increased uric acid, decreased total neutrophil count, decreased hemoglobin, increased activated partial thromboplastin time, decreased potassium, increased aspartate aminotransferase (AST), leukopenia, thrombocytopenia, and increased alanine aminotransferase (ALT).

In addition to the reactions and abnormalities noted above,Clinical studies of Imdelltra have reported other warnings and precautions. These include cytokine release syndrome, neurotoxicity (including ICANS), cytopenias, infections, hepatotoxicity, allergies, embryo-fetal toxicity, etc. To combat these problems, doctors may recommend stopping the drug and gradually reducing the dose as the patient recovers, or permanently discontinuing it depending on the severity.

It should be noted that the above side effects and warnings are based on Imdelltra’s clinical research results and do not mean that every patient will experience these reactions. When using this drug, your doctor will evaluate the patient on a case-by-case basis and weigh the potential benefits and risks.